Tue, Jul 29, 2014, 4:09 AM EDT - U.S. Markets open in 5 hrs 21 mins

Recent

% | $
Click the to save as a favorite.

Isis Pharmaceuticals, Inc. Message Board

  • dinepat203 dinepat203 Nov 28, 2012 10:14 AM Flag

    60K SHORT WAITING STOP LOSS?

    GOOD TRY....

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If approved, Kynamro/mipomersen will be marketed by Sanofi’s Genzyme unit, a power play in rare diseases.

      While the FDA seems pleased with the risk/benefit profile of lomitapide for HoFH, there is always the risk of a “chemistry, manufacturing, and controls” or “CMC” issue delaying approval. Also, AEGR intends to market the drug alone in the US and EU – since the company has no commercial experience, there remains some execution risk until we see how the product launch and potential competitive positioning with mipomersen proceeds.

      Sentiment: Strong Buy

 
ISIS
30.16+0.02(+0.07%)Jul 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.